The first FDA-cleared artificial intelligence diagnostic system for medical imaging, developed by Qlarity Imaging, a portfolio company of Paragon Biosciences, was selected as a “game-changing” innovation by a panel of global business leaders.
Chicago, IL, March 19, 2020 – Qlarity Imaging today announced that QuantX, the first –ever FDA-cleared computer-aided breast cancer diagnosis system in radiology, is the recipient of a gold level Edison Award in the Medical category. Qlarity Imaging improves patient care by extracting clinical insights from existing medical images. The company builds products that give radiologists diagnostic AI insights they do not have today.
Fellow nominees included some of the most innovative products, services, and businesses for the year 2020. The QuantX diagnostic system was chosen as a winner by a panel of over 3,000 leading business executives from around the world. “After a thorough review, the Edison Awards Judges recognized QuantX as a game-changing innovation standing out among the best new products and services launched in their category,” said Frank Bonafilia, Executive Director of the Edison Awards.
“Qlarity Imaging leveraged artificial intelligence to develop QuantX, which holds the potential to more accurately diagnose the devastating disease of breast cancer from MR images,” said Meg Harrison, Qlarity COO and Head of Product. “We are thrilled to receive this recognition from the Edison Awards. It reinforces our commitment to find even more life-saving advances in radiology.” In 2019, the QuantX system was named one of the best inventions of the year by TIME magazine.
Qlarity Imaging is a portfolio company of Paragon Biosciences, the Chicago-based life science innovator that accelerates life-science breakthroughs by building and supporting visionary companies.
Paragon was recently recognized by Fast Company as one of the 10 Most Innovative Health Companies of 2020. Qlarity Imaging is highlighted in the magazine for the QuantX system for helping radiologists detect breast cancer with 20 % greater accuracy than other available technologies.
About Qlarity Imaging:
Qlarity Imaging improves patient care by building AI-driven products that provide diagnostic AI insights which radiologists do not have access to today. One of Qlarity’s initial products, QuantX Advanced, is the first FDA-cleared, computer-aided breast cancer diagnosis software for radiology. For more information, please visit www.qlarityimaging.com.
About the Edison Awards:
The Edison Awards is the world’s most revered Innovation Award dedicated to recognizing and honoring the best in innovation and innovators since 1987. For more information about the Edison Awards complete program and a list of past winners, visit www.edisonawards.com.
About Paragon Biosciences:
Paragon is a life science innovator that invests in, builds, and advises bioscience companies. Our mission is to solve complex human and societal challenges by accelerating development of novel therapies and life science breakthroughs. For more information, please visit: ParagonBioSci.com.
Qlarity Imaging/Paragon Biosciences